Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Milestone Pharmaceuticals (MIST) Drops -45% Over 30 Days on CARDAMYST Launch Concerns

Milestone Pharmaceuticals (MIST) Drops -45% Over 30 Days on CARDAMYST Launch Concerns

Key Takeaways

  • Milestone Pharmaceuticals (MIST) shares fell roughly 45% over the last 30 days, tumbling from near $0.70 to the $0.38–$0.40 range as selling intensified after third-quarter results.
  • The decline accelerated sharply in mid-November following the company's Q3 2026 earnings report and a wave of analyst price-target reductions.
  • Despite a quarterly revenue beat, investor focus shifted to slower-than-expected CARDAMYST launch traction, prompting several firms to lower their targets on the stock.
  • The broader quarterly trend is also deeply negative, with shares down roughly 60% from levels near $1.03 in late August.
  • Management announced a cost-reduction program targeting about 30% lower operating expenses, extending its cash runway into late 2028.

Company Background and Focus on CARDAMYST

Milestone Pharmaceuticals Inc. is a Montreal, Canada-based biopharmaceutical company focused on developing and commercializing cardiovascular medicines. Its flagship product is CARDAMYST (etripamil), a self-administered calcium channel blocker nasal spray approved to convert acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to normal sinus rhythm in adults. The company is also developing etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR), and it maintains a license and collaboration agreement with Corxel Pharmaceuticals. Because CARDAMYST is the company's first commercial product, investors closely track its launch metrics, prescription trends, insurance coverage progress, and the company's cash runway. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Recent Stock Performance: Last 30 Days and the Quarter

Over the last 30 days, MIST shares have fallen roughly 45%, declining from about $0.70 in late October to the $0.38–$0.40 area. The move was not linear: the stock drifted lower through early November before dropping sharply around November 13–16, when the third-quarter report and subsequent analyst actions triggered heavy selling. The quarterly picture is even weaker, with the stock down approximately 60% from levels near $1.03 in late August, extending a longer downtrend that took shares well off their 52-week high of $3.06. From what I see, this kind of rapid repricing often signals a shift in how the market views near-term execution.

Key Drivers Behind the Recent Decline

The most significant catalyst was the company's third-quarter 2026 earnings release on November 13. Milestone reported quarterly revenue of approximately $2.96 million, above consensus estimates near $1 million, and a narrower-than-expected net loss per share. However, the market's reaction focused on the pace of the CARDAMYST commercial launch rather than the headline beat. Concerns about slower prescription growth and lower product sales prompted a series of analyst price-target reductions, including cuts by Piper Sandler, Wells Fargo, TD Cowen, and H.C. Wainwright, which intensified selling pressure over the following sessions.

Alongside the report, management announced a cost-reduction initiative targeting roughly 30% lower operating expenses, which it said would extend the company's cash runway into late 2028. While this strengthened the balance-sheet outlook, the accompanying emphasis on cost discipline was read by some investors as a sign that near-term revenue growth remains constrained, adding to the negative sentiment.

Broader Quarterly Context and Launch Realities

The quarterly decline reflects a broader repricing of the CARDAMYST launch opportunity. After an initial post-approval rally earlier in the year, investor enthusiasm cooled as the realities of commercial execution—including insurance coverage hurdles and gradual prescription uptake—came into focus. The stock slid from roughly $1.20 in early July to around $1.03 by late August, then continued lower through the fall as coverage timelines extended and revenue expectations were recalibrated. The Q3 report crystallized these concerns, accelerating a downtrend that had been building for months as the market shifted from anticipation of the launch toward scrutiny of its actual commercial trajectory. I’m watching this closely because launch metrics in biotech often set the tone for months ahead.

Factors to Monitor Going Forward

Several factors are likely to shape MIST's trajectory in the months ahead. First, investors will monitor CARDAMYST prescription volume and commercial coverage expansion, particularly progress toward Medicare reimbursement, which management has indicated may take longer to achieve. Second, the execution of the announced cost-reduction program and its impact on the company's cash runway will be closely scrutinized. Third, the ReVeRA-301 Phase 3 program for etripamil in AFib-RVR, with a data readout expected in the second half of 2028, represents a longer-term catalyst. Finally, additional analyst revisions, competitive dynamics in the cardiovascular space, and broader biotech sentiment will continue to influence trading. As with all early-stage commercial biotech companies, execution risk and capital-market conditions remain key considerations.

Exploring AI-Driven Trading Approaches

I’ve found that reviewing automated strategies can add useful perspective when analyzing volatile names like this one. Tickeron’s Trending AI Robots page curates a selection of automated trading strategies from a much larger universe of hundreds of AI-powered bots that trade thousands of tickers. Rather than listing every available bot, the page highlights top-performing and most relevant strategies, making it easier to identify approaches that may align with specific market conditions. The bots vary in strategy, timeframe, and performance metrics, so investors can review options suited to different risk tolerances and holding periods. For those interested in data-driven, algorithm-based approaches to navigating volatile names like MIST, the Trending AI Robots section offers a useful starting point.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MIST

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


MIST's RSI Indicator stoops into oversold zone

The RSI Indicator for MIST moved into overbought territory on November 19, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +26.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIST advanced for three days, in 220 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

MIST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIST as a result. In 71 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The Moving Average Convergence Divergence Histogram (MACD) for MIST turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 38 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for MIST entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.213) is normal, around the industry mean (3.596). P/E Ratio (-1.174) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (44.843) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. MIST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -16%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer and manufacturer of cardiovascular medicines

Industry Biotechnology

Industry
Pharmaceuticals Major
Address
1111 Dr. Frederik-Phillips Boulevard
Phone
+1 514 336-0444
Employees
38
Web
https://www.milestonepharma.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.